Jo-Anna Reems, PhD

Research Interests

  • Stem Cell Biology
  • Regenerative Medicine

Languages

  • English

Academic Information

  • Departments: Internal Medicine - Research Professor
  • Divisions: Hematology/BMT

Academic Office Information

  • 801-581-2980
  • 675 Arapeen Suite 300
    Salt Lake City, UT 84108

Academic Bio

Jo-Anna Reems, Ph.D. is Research Professor in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. She is also the Scientific Director of the University of Utah Health Care Cell Therapy & Regenerative Medicine Facility, which is FACT accredited. Dr. Reems is certified by the American Society of Clinical Pathologists as a Medical Technologist, and a Specialist in Blood Banking.

The Reems Laboratory focuses on delivering novel cellular products that have the potential to improve the quality of life for patients. In particular, she is interested in understanding the regulatory mechanisms responsible for the proliferation and differentiation of hematopoietic stem/progenitor cells along the megakaryocte (MK) lineage. Ultimately, for the purpose of developing an in vitro approach to amplify hematopoietic stem cells, to direct the stem cells along the MK lineage to produce MK progenitor cells, and to then selectively direct mature MK progeny cells to produce platelets for transfusion purposes. The intended purpose is to someday help supplement platelet inventories at Blood Banks. The strategy to achieve this goal is based on testing the following hypotheses: 1) rational modulation of extrinsic and intrinsic factors will allow expansion of primary MKs in a manner that maintains an immature phenotype; 2) changes in culture conditions will facilitate terminal maturation and platelet shedding of expanded MKs; and 3) platelet-like fragments, formed under these conditions, will have hemostatic activity, comparable to normal platelets.

In her role as the Scientific Director for the Stem Cell Facility, Dr. Reems' vision is to create a premier Cell Therapy and Regenerative Medicine Center of Excellence for the state of Utah that facilitates the translation of cutting-edge cell therapy and tissue engineered research into clinical products that extend and improve the quality of life of individuals suffering from debilitating diseases and injuries.

Dr. Reems obtained her B.S. in Medical Technology at the University of Colorado at Boulder. She then earned her Ph.D. in Biochemistry at the University of Colorado Health Sciences Center in Denver, Colorado. After her doctoral studies, Dr. Reems completed a Research Fellowship at Fred Hutchinson Cancer Research Center, with a focus on Regulators of Hematopoiesis. Prior to joining the University of Utah as faculty, Dr. Reems functioned as the Scientific Director of the Cell Therapy Facility at Puget Sound Blood Center in Seattle, Washington.

Education History

Type School Degree
Research Fellow Fred Hutchinson Cancer Research Center
Focus: Regulators of Hematopoiesis
Research Fellow
Doctoral Training University of Colorado Health Sciences Center
Biochemistry
Ph.D.
Certification American Red Cross
Specialist in Blood Banking
Certification
Undergraduate University of Colorado
Medical Technology
B.S.

Selected Publications

Journal Article

  1. Strunk D, Lozano M, Marks DC, Loh YS, Gstraunthaler G, Schennach H, Rohde E, Laner-Plamberger S, Oller M, Nystedt J, Lotfi R, Rojewski M, Schrezenmeier H, Bieback K, Schafer R, Bakchoul T, Waidmann M, Jonsdottir-Buch SM, Montazeri H, Sigurjonsson OE, Iudicone P, Fioravanti D, Pierelli L, Introna M, Capelli C, Falanga A, Takanashi M, Lomicronpez-Villar O, Burnouf T, Reems JA, Pierce J, Preslar AM, Schallmoser K (2018). International Forum on GMP-grade human platelet lysate for cell propagation: summary. Vox Sang, 113(1), 80-87.
  2. Strunk D, Lozano M, Marks DC, Loh YS, Gstraunthaler G, Schennach H, Rohde E, Laner-Plamberger S, Oller M, Nystedt J, Lotfi R, Rojewski M, Schrezenmeier H, Bieback K, Schafer R, Bakchoul T, Waidmann M, Jonsdottir-Buch SM, Montazeri H, Sigurjonsson OE, Iudicone P, Fioravanti D, Pierelli L, Introna M, Capelli C, Falanga A, Takanashi M, Lopez-Villar O, Burnouf T, Reems JA, Pierce J, Preslar AM, Schallmoser K (2018). International Forum on GMP-grade human platelet lysate for cell propagation. Vox Sang, 113(1), e1-e25.
  3. Winter JM, Jacobson P, Bullough B, Christensen AP, Boyer M, Reems JA (2014). Long-term effects of cryopreservation on clinically prepared hematopoietic progenitor cell products. Cytotherapy, 16(7), 965-75.
  4. Mojica-Henshaw MP, Jacobson P, Morris J, Kelley L, Pierce J, Boyer M, Reems JA (2013). Serum-converted platelet lysate can substitute for fetal bovine serum in human mesenchymal stromal cell cultures. Cytotherapy, 15(12), 1458-68.
  5. Sun S, Wang W, Latchman Y, Gao D, Aronow B, Reems JA (2013). Expression of plasma membrane receptor genes during megakaryocyte development. Physiol Genomics, 45(6), 217-27.
  6. Pamphilon D, Selogie E, McKenna D, Cancelas-Peres JA, Szczepiorkowski ZM, Sacher R, McMannis J, Eichler H, Garritsen H, Takanashi M, van de Watering L, Stroncek D, Reems JA (2013). Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Cytotherapy, 15(3), 255-62.
  7. Nicoud IB, Clarke DM, Taber G, Stolowski KM, Roberge SE, Song MK, Mathew AJ, Reems JA (2012). Cryopreservation of umbilical cord blood with a novel freezing solution that mimics intracellular ionic composition. Transfusion, 52(9), 2055-62.
  8. Tseng HY, Sun S, Shu Z, Ding W, Reems JA, Gao D (2011). A Microfluidic Study of Megakaryocytes Membrane Transport Properties to Water and Dimethyl Sulfoxide at Suprazero and Subzero Temperatures. Biopreserv Biobank, 9(4), 355-362.
  9. Wang W, Gilligan DM, Sun S, Wu X, Reems JA (2011). Distinct functional effects for dynamin 3 during megakaryocytopoiesis. Stem Cells Dev, 20(12), 2139-51.
  10. Reems JA (2011). A journey to produce platelets in vitro. Transfusion, 51 Suppl 4, 169S-176S.
  11. Rosskopf K, Ragg SJ, Worel N, Gromme M, Preijers FW, Braakman E, Schuurhuis GJ, van Riet I, Wendel S, Fontao-Wendel R, Lazar A, Goldman M, Halpenny M, Giulivi A, Letcher B, McGann L, Korhonen M, Arvola A, Humpe A, Buwitt-Beckmann U, Wiesneth M, Schauwecker P, Schrezenmeier H, Bonig H, Henschler R, Seifried E, Accorsi P, Bonfini T, Takanashi M, van Beckhoven JM, Brand A, Gounder D, Wong A, Dooccey R, Forrest E, Galea G, Smythe J, Pawson R, Reems JA, Oh J, Reesink HW, Panzer S (2011). Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow). Vox Sang, 101(3), 255-75.
  12. Nawrot M, McKenna DH, Sumstad D, McMannis JD, Szczepiorkowski ZM, Belfield H, Grassman E, Temples T, Nielsen D, Yuan N, Wognum B, Reems JA (2011). Interlaboratory assessment of a novel colony-forming unit assay: a multicenter study by the cellular team of Biomedical Excellence for Safer Transfusion (BEST) collaborative. Transfusion, 51(9), 2001-5.
  13. Spellman S, Hurley CK, Brady C, Phillips-Johnson L, Chow R, Laughlin M, McMannis J, Reems JA, Regan D, Rubinstein P, Kurtzberg J (2011). Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. Cytotherapy, 13(7), 848-55.
  14. Pamphilon D, Curnow E, Belfield H, Reems JA, McMannis J, Lecchi L, Szczepiorkowski Z, McKenna D (2011). Storage characteristics of cord blood progenitor cells: report of a multicenter study by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Transfusion, 51(6), 1284-90.
  15. Liang XM, Han SJ, Reems JA, Gao D, Sniadecki NJ (2010). Platelet retraction force measurements using flexible post force sensors. Lab Chip, 10(8), 991-8.
  16. Ding W, Zhou X, Heimfeld S, Reems JA, Gao D (2010). A steady-state mass transfer model of removing CPAs from cryopreserved blood with hollow fiber modules. J Biomech Eng, 132(1), 011002.
  17. Pamphilon DH, Selogie E, Szczepiorkowski ZM, BEST Collaborative Cellular Therapies Team (2010). Transportation of cellular therapy products: report of a survey by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) collaborative. Vox Sang, 99, 168-73.

Abstract

  1. Stroncek DF, McKeena DH, Takahashi M, Fontaine M, Pati S, Jin P, Peterson E, Benedetti E, Reems J (2018). Center Method Contributes more to MSC Variability than does Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) [Abstract]. Transfusion, 58(S2), Abst# 3771.
  2. Reems JA, Fontaine, M (2018). Variatons in Novel Cellular Therapy Products Manufacturing [Abstract]. Transfusion, 58(S2), Abst# 4175.
  3. Preslar A, Homsombath A, Hsieh F, Roig J, Boyer M, Couriel D, Reems JA (3/22/2018). Comparison of the continuous mononuclear cell and mononuclear cell apheresis protocols on the spectra optial apheresis system for collecting autologous and allogeneic peripheral blood stem cells (PBSCs). Abst 193 [Abstract]. Biology of Blood and Marrow Transplantation, 24(3), 5151.
  4. Shyr D, Hsieh F, Reems, JA (3/15.2018). Single center experience with total nucleated cell, CD34 and CD3 cell yield from bone marrow harvests in both adult and pediatric donors. Abst. 218 [Abstract]. Biology of Blood and Marrow Transplantation, 24(3), S168.
  5. Takanashi M, Selogie E, Reems JA, Stroncek D, Fontaine MJ, Girdelstone J, Garritsen HSP, Young P, McKenna DH, Szczepiorkowski ZM (2017). Current practices for viability testing of cryopreserved cord blood products: an international survey by the cellulalr therapy team of the biomedical excellence for safer transfusion collaborative [Abstract]. Vox Sanguinis.
  6. Reems JA, Jacobson P, Fisher S, Ma Y, Jin P, Stroncek D, Pierce J (2016). Comparative analysis of industrial scale human platelet lysate (PL) preparations [Abstract]. Transfusion, 56, S5-010A.
  7. Ma Y, Reilly S, Fischer, SE, Henshaw M, Pierce J, Poudel AR, Reems JA (2015). Human platelet lysate produced at industrial scale for use as fetal bovine serum replacement in cellmanufacturing protocols [Abstract]. Cytotherapy, 17, P141.
  8. Pierce J, Jacobson P, Regginello T, Wynalek B, Flanagan F (2015). Human amnion membrane versus amnion chorion implants in athymic nude mice [Abstract]. Cytotherapy, 17(6), S71.
  9. Pierce J, Jacobson P, Regginello T, Wynalek B, Flanagan F, Reems JA (2015). Characterization of human amnion membrane versus amnion chorion preparations. [Abstract]. Cytotherapy, 17(6S), Abst. P241.
  10. Stroncek D, Jin P, Reems JA, Cancelas J, Nayak RC, Shaw G, OBrien T, Mckenna DH, Armant M, Silberstein LE, Gee A, Hei DJ, Hematti P, Civini S, Sabatino M, Robey, PG (2015). Comparison of bone marrow stromal cells (BMSC) production methods and products from multiple centers [Abstract]. Cytotherapy, 17(6), S51.
  11. Stroncek DF, Ping J, Reems JA, Cancelas J, Nayak R, Shaw G, OBrien T, McKeena DH, Arman A, Silberstein L, Gee AP, Hei DJ, Hematti P, Civini S, Sabatino M, Robey PG (2015). Comparison of bone marrow stromal (BMSC) production methods and products from multiple centers [Abstract]. Cytotherapy, 17(6S), Abst. P175.
  12. Jacobson P, Pierce J, Preslar A, Phibbs J, Reems JA (2015). Amniotic fluid collection from scheduled c-section deliveries results in consistent fluid chemistries and therapeutic levels of adherent cells [Abstract]. Cytotherapy, 17(6S), Abst. P242.
  13. Preslar A, Tamara L, Jacobson P, Reems JA (2015). Changing anticoagulation management: ACD-A only collections with Spectra Optia versus heparinized ACD-A collections with COBE Spectra [Abstract]. Cytotherapy, 17(6S), Abst. P207.

Patent

  1. Reems JA, Pierce J (2019). Therapeutic Compositions. U.S. Patent No. 15450566. Washington, D.C.:U.S. Patent and Trademark Office.